Driehaus Capital Management’s Ascendis Pharma A/S ASND Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $18.7M | Sell |
70,061
-57,501
| -45% | -$13.4M | 0.11% | 238 |
|
|
2026
Q1 | $29.2M | Sell |
127,562
-28,710
| -18% | -$6.44M | 0.21% | 152 |
|
|
2025
Q4 | $33.3M | Sell |
156,272
-22,896
| -13% | -$4.73M | 0.23% | 144 |
|
|
2025
Q3 | $35.6M | Sell |
179,168
-15,940
| -8% | -$2.97M | 0.26% | 132 |
|
|
2025
Q2 | $33.7M | Buy |
195,108
+43,279
| +29% | +$7.05M | 0.27% | 122 |
|
|
2025
Q1 | $23.7M | Buy |
151,829
+63,333
| +72% | +$9.05M | 0.23% | 135 |
|
|
2024
Q4 | $12.2M | Sell |
88,496
-25,818
| -23% | -$3.39M | 0.1% | 224 |
|
|
2024
Q3 | $17.1M | Buy |
114,314
+32,918
| +40% | +$4.45M | 0.15% | 190 |
|
|
2024
Q2 | $11.1M | Sell |
81,396
-18,924
| -19% | -$2.57M | 0.11% | 207 |
|
|
2024
Q1 | $15.2M | Buy |
+100,320
| New | +$14.3M | 0.15% | 196 |
|
|
2023
Q2 | – | Sell |
-180,234
| Closed | -$19.3M | – | 393 |
|
|
2023
Q1 | $19.3M | Buy |
180,234
+7
| +0% | +$801 | 0.27% | 120 |
|
|
2022
Q4 | $22M | Buy |
180,227
+56,887
| +46% | +$6.6M | 0.33% | 98 |
|
|
2022
Q3 | $12.7M | Sell |
123,340
-14,170
| -10% | -$1.34M | 0.19% | 158 |
|
|
2022
Q2 | $12.8M | Buy |
137,510
+8,185
| +6% | +$771K | 0.21% | 166 |
|
|
2022
Q1 | $15.2M | Buy |
129,325
+48,079
| +59% | +$5.57M | 0.19% | 172 |
|
|
2021
Q4 | $10.9M | Buy |
81,246
+99
| +0.1% | +$14.7K | 0.11% | 229 |
|
|
2021
Q3 | $12.9M | Buy |
81,147
+24,914
| +44% | +$3.41M | 0.15% | 198 |
|
|
2021
Q2 | $7.4M | Buy |
56,233
+3,844
| +7% | +$512K | 0.1% | 252 |
|
|
2021
Q1 | $6.75M | Sell |
52,389
-131,931
| -72% | -$20.1M | 0.1% | 256 |
|
|
2020
Q4 | $30.7M | Buy |
184,320
+19,219
| +12% | +$3.18M | 0.5% | 56 |
|
|
2020
Q3 | $25.5M | Sell |
165,101
-21,206
| -11% | -$3.05M | 0.52% | 49 |
|
|
2020
Q2 | $27.6M | Buy |
186,307
+21,063
| +13% | +$2.89M | 0.67% | 34 |
|
|
2020
Q1 | $18.6M | Buy |
165,244
+9,832
| +6% | +$1.28M | 0.62% | 42 |
|
|
2019
Q4 | $21.6M | Buy |
155,412
+12,807
| +9% | +$1.42M | 0.57% | 44 |
|
|
2019
Q3 | $13.7M | Sell |
142,605
-726
| -0.5% | -$81K | 0.45% | 60 |
|
|
2019
Q2 | $16.5M | Sell |
143,331
-27,534
| -16% | -$3.29M | 0.52% | 54 |
|
|
2019
Q1 | $20.1M | Buy |
170,865
+145,451
| +572% | +$12.7M | 0.76% | 29 |
|
|
2018
Q4 | $1.59M | Sell |
25,414
-24,492
| -49% | -$1.54M | 0.07% | 244 |
|
|
2018
Q3 | $3.54M | Buy |
49,906
+10,313
| +26% | +$710K | 0.11% | 220 |
|
|
2018
Q2 | $2.63M | Sell |
39,593
-9,428
| -19% | -$620K | 0.09% | 241 |
|
|
2018
Q1 | $3.21M | Buy |
+49,021
| New | +$2.76M | 0.11% | 209 |
|
|
2017
Q4 | – | Sell |
-99,328
| Closed | -$3.6M | – | 530 |
|
|
2017
Q3 | $3.6M | Buy |
+99,328
| New | +$2.85M | 0.14% | 192 |
|
Other funds holding ASND
RCM
ACA
JT
Driehaus Capital Management's ASND Position: Q2 2026 in Review
Driehaus Capital Management reduced its Ascendis Pharma A/S (ASND) stake by 45% in Q2 2026, selling an estimated $13.4M and leaving 70,061 shares worth $18.7M. The position accounts for 0.11% of the portfolio, ranked #238.
Driehaus Capital Management first reported a position in ASND in Q3 2017 and has held it in 32 quarters since. The position peaked at $35.6M in Q3 2025. 312 funds tracked by Wall St. Rank hold ASND as of Q2 2026.
- Driehaus Capital Management held 70,061 shares of Ascendis Pharma A/S worth $18.7M as of Q2 2026.
- Driehaus Capital Management sold 57,501 Ascendis Pharma A/S shares in Q2 2026, an estimated $13.4M.
- Ascendis Pharma A/S made up 0.11% of Driehaus Capital Management's portfolio in Q2 2026, its #238 holding.
- Driehaus Capital Management first reported a position in Ascendis Pharma A/S in Q3 2017 and has held it in 32 quarters since.
- Driehaus Capital Management's Ascendis Pharma A/S position peaked at $35.6M in Q3 2025.
- 312 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2026.
Based on Driehaus Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.